TKNO
NASDAQ
$5.30
Alpha Teknova Inc (TKNO)
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology industry, specializing in the development of essential biological reagents and supplements that facilitate advancements in life sciences research and biomanufacturing. The company's innovative offerings are integral to high-demand sectors, including vaccine development, cell and gene therapy, and diagnostic testing, underscoring its commitment to quality and superior customer support. With a robust biotechnology foundation and a focus on innovation, Alpha Teknova is well-positioned to capitalize on growth opportunities within the rapidly evolving life sciences market, enhancing its appeal to institutional investors seeking strategic investments.
Sector:
Healthcare
Buy
Target: $9 (+69.81%)
Market Cap
$284M
Free Cash Flow Yield
-3.20%
Beta (5Y)
1.59
Price Chart
Valuation
Market Cap$284M
P/S6.78
P/B4.47
Profitability
Total Revenue (TTM)$42M
Gross Profit (TTM)$14M
EBITDA-$9.97M
Profit Margin-41.1%
Operating Margin-38.8%
EPS-$0.32
Financial Health
Debt-to-Equity20.3%
Free Cash Flow Yield-3.20%
Growth & Risk
Beta (5Y)1.59
Sharpe Ratio0.59